All In Biotech

NDA 206229 · Medicines360

Liletta

Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System

Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Feb 26, 2015

Approved uses

7

Original approval plus efficacy supplements

Registered trials

354

70 Phase 3, 26 recruiting

FAERS reports

14,329

3,453 serious, 60 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2023.

LILETTA is a progestin-containing intrauterine system indicated for: Prevention of pregnancy for up to 8 years ( 1.1 ) Treatment of heavy menstrual bleeding for up to 5 years in patients who choose intrauterine contraception as their method of contraception ( 1.2 ) 1.1 Contraception LILETTA is indicated for prevention of pregnancy for up to 8 years. 1.2 Heavy Menstrual Bleeding LILETTA is indicated for the treatment of heavy menstrual bleeding for up to 5 years in patients who choose to use intrauterine contraception as their method of contraception; replace after the end of the fifth year if continued treatment of heavy menstrual bleeding is needed.

Mechanism: The local mechanism by which continuously released LNG provides contraception has not been conclusively demonstrated. Studies of LNG-releasing IUSs suggest several mechanisms for pregnancy prevention: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm mobility and function (capacitation), and alteration of the endometrium.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LILETTA · LEVONORGESTREL 52MG · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device expulsion5,536
  • procedural pain1,859
  • device dislocation1,163
  • drug ineffective626
  • off label use546
  • uterine perforation543
  • uterine spasm392
  • nausea295
  • pain278
  • headache230
  • dizziness200
  • abdominal pain199

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200439
200539
200637
200727
200822
200945
201064
201193
2012101
201345
201433
2015116
2016657
20171,032
2018476
20191,199
20201,648
20211,420
20221,672
20232,125
20241,282
20251,238
2026919

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Liletta (Levonorgestrel)

2024 spending

$30K

Beneficiaries

34

34 claims

Per beneficiary

$870

$869.64 per unit

View as table
YearSpending
2020$12,830
2021$32,594
2022$23,823
2023$27,879
2024$29,568

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,410 on PubMed

Sponsor: Medicines360

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.